EMEND IV 115 MG
FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) : 115 MG · DIN 02324679 · MERCK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is EMEND IV?
EMEND IV 115 MG contains FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) : 115 MG. It is listed in the Health Canada Drug Product Database under DIN 02324679, held by MERCK CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 28-Oct-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EMEND IV used for?
Prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy and moderately emetogenic cancer chemotherapy (in women).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02324679 |
|---|---|
| Brand name | EMEND IV |
| Generic / active ingredient | FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) : 115 MG |
| Manufacturer | MERCK CANADA INC |
| Strength | 115 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | A04AD OTHER ANTIEMETICS |
| AHFS class | 56:22.32 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Oct-2010 |
| Original market date | 2009-04-30 00:00:00 |
How is it administered?
115 mg administered intravenously on Day 1 as part of a 3-day regimen with oral aprepitant, a 5-HT3 antagonist, and dexamethasone. Reduce dexamethasone dose by 50%.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (refer to STORAGE AND STABILITY section on page 20).
How is it supplied?
115 mg fosaprepitant/vial (as fosaprepitant dimeglumine).
Contraindications
Hypersensitivity to fosaprepitant, aprepitant, polysorbate 80; concurrent use with pimozide, terfenadine, astemizole, or cisapride due to CYP3A4 inhibition.
Warnings and precautions
Drug interactions (CYP3A4, Warfarin, Hormonal contraception); immediate hypersensitivity reactions (flushing, erythema, dyspnea) during infusion.
What can be used instead?
Other Canadian products sharing ATC code A04AD OTHER ANTIEMETICS. 2 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EMEND IV | 150 MG | POWDER FOR SOLUTION | MERCK CANADA INC | MARKETED | DIN 02363356 |
| FOSAPREPITANT FOR INJECTION | 150 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02549379 |
| FOSAPREPITANT | 150 MG | POWDER FOR SOLUTION | APOTEX INC | APPROVED | DIN 02436264 |
Who else supplies OTHER ANTIEMETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OTHER ANTIEMETICS appears in 8 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.